{"DataElement":{"publicId":"8137754","version":"2","preferredName":"Disease Response Domain Lesion Overall Response Evaluation Leukemia Type","preferredDefinition":"Text term that represents the overall lesion response evaluation leukemia type.","longName":"RS_RSORRES_OVRLRESP","context":"CCTG","contextVersion":"1","DataElementConcept":{"publicId":"6941857","version":"1","preferredName":"Disease Response Domain Lesion Overall Response","preferredDefinition":"A domain for disease response evaluations._A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._An assessment of the overall response of the disease to the therapy.","longName":"6608777v1.0:6941855v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6608777","version":"1","preferredName":"Disease Response Domain","preferredDefinition":"A domain for disease response evaluations.","longName":"C107097","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response Domain","conceptCode":"C107097","definition":"A domain for disease response evaluations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6DD03A-0CB9-71AE-E053-F662850AB42C","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"ONEDATA","dateModified":"2019-01-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6941855","version":"1","preferredName":"Lesion Overall Response","preferredDefinition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.:An assessment of the overall response of the disease to the therapy.","longName":"C3824:C96613","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Overall Response","conceptCode":"C96613","definition":"An assessment of the overall response of the disease to the therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92C7595D-164F-595C-E053-F662850A219D","latestVersionIndicator":"Yes","beginDate":"2019-09-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-17","modifiedBy":"ONEDATA","dateModified":"2019-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"92C7595D-1660-595C-E053-F662850A219D","latestVersionIndicator":"Yes","beginDate":"2019-09-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-17","modifiedBy":"COOPERM","dateModified":"2020-06-04","changeDescription":"Created for CDISC aligned NCI CRF standards task. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"8137611","version":"2","preferredName":"Overall Disease Response Evaluation Leukemia Type","preferredDefinition":"Including everything._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria._Something distinguishable as an identifiable class based on common qualities.","longName":"ONCRSR_LEUK_D","context":"CCTG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Death from Indeterminate Cause","valueDescription":"Indeterminate Etiology Dead","ValueMeaning":{"publicId":"8137613","version":"1","preferredName":"Indeterminate Etiology Dead","longName":"8137613","preferredDefinition":"Cannot distinguish between two or more possible values in the current context.: The cause of a disease or abnormal condition.: The cessation of life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate","conceptCode":"C48658","definition":"Cannot distinguish between two or more possible values in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Etiology","conceptCode":"C16390","definition":"The cause of a disease or abnormal condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dead","conceptCode":"C28554","definition":"The cessation of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD766A5-2EC2-5E13-E053-4EBD850AD9C1","latestVersionIndicator":"Yes","beginDate":"2022-04-04","endDate":null,"createdBy":"WINCHC","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F910B966-4CD1-1F7F-E053-731AD00AFFC2","beginDate":"2022-04-04","endDate":null,"createdBy":"WINCHC","dateCreated":"2023-04-11","modifiedBy":"ONEDATA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Death in Aplasia","valueDescription":"Agenesis Dead","ValueMeaning":{"publicId":"8137614","version":"1","preferredName":"Agenesis Dead","longName":"8137614","preferredDefinition":"A congenital abnormality resulting in the absence of an anatomical structure. (NCI): The cessation of life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agenesis","conceptCode":"C120864","definition":"A congenital abnormality resulting in the absence of an anatomical structure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dead","conceptCode":"C28554","definition":"The cessation of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD766A5-2EE8-5E13-E053-4EBD850AD9C1","latestVersionIndicator":"Yes","beginDate":"2022-04-04","endDate":null,"createdBy":"WINCHC","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F910B966-4CD2-1F7F-E053-731AD00AFFC2","beginDate":"2022-04-04","endDate":null,"createdBy":"WINCHC","dateCreated":"2023-04-11","modifiedBy":"ONEDATA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Morphologic Leukemia-Free State (MLFS)","valueDescription":"Leukemia State Disease Free","ValueMeaning":{"publicId":"8137615","version":"1","preferredName":"Leukemia State Disease Free","longName":"8137615","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.: The way something is with respect to its main attributes.: An indication that an individual shows no signs of having or carrying a disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"State","conceptCode":"C25687","definition":"The way something is with respect to its main attributes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Free","conceptCode":"C173158","definition":"An indication that an individual shows no signs of having or carrying a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD766A5-2F0F-5E13-E053-4EBD850AD9C1","latestVersionIndicator":"Yes","beginDate":"2022-04-04","endDate":null,"createdBy":"WINCHC","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F910B966-4CD3-1F7F-E053-731AD00AFFC2","beginDate":"2022-04-04","endDate":null,"createdBy":"WINCHC","dateCreated":"2023-04-11","modifiedBy":"ONEDATA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Complete Remission (CR)","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3951936","version":"1","preferredName":"Complete Remission","longName":"3951936v1.00","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB155E17-C5DA-CEC3-E040-BB89AD4342C2","latestVersionIndicator":"Yes","beginDate":"2013-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-13","modifiedBy":"SOKKERL","dateModified":"2023-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F910B966-4CD4-1F7F-E053-731AD00AFFC2","beginDate":"2017-08-30","endDate":null,"createdBy":"WINCHC","dateCreated":"2023-04-11","modifiedBy":"ONEDATA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Inevaluable (NE)","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3855538","version":"1","preferredName":"Unevaluable","longName":"3855538","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F3FD8B-328D-C859-E040-BB89AD43580F","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F910B966-4CD5-1F7F-E053-731AD00AFFC2","beginDate":"2017-08-30","endDate":null,"createdBy":"WINCHC","dateCreated":"2023-04-11","modifiedBy":"ONEDATA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Complete Response with Incomplete Blood Count Recovery (CRi)","valueDescription":"Complete Response with Incomplete Bone Marrow Recovery","ValueMeaning":{"publicId":"6674540","version":"1","preferredName":"Complete Response with Incomplete Bone Marrow Recovery","longName":"6674540","preferredDefinition":"The disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Response with Incomplete Bone Marrow Recovery","conceptCode":"C103385","definition":"The disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-E035-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"MMADDINENI","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":"2023.3.22 Alt VM added per ticket request CADSR0002191. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F910B966-4CD6-1F7F-E053-731AD00AFFC2","beginDate":"2022-04-04","endDate":null,"createdBy":"WINCHC","dateCreated":"2023-04-11","modifiedBy":"ONEDATA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Primary Refractory disease","valueDescription":"Refractory","ValueMeaning":{"publicId":"2566882","version":"1","preferredName":"Refractory","longName":"2566882","preferredDefinition":"Not responding to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory","conceptCode":"C38014","definition":"Not responding to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D24F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-22","endDate":null,"createdBy":"PWEST","dateCreated":"2003-08-22","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F910B966-4CD7-1F7F-E053-731AD00AFFC2","beginDate":"2022-04-04","endDate":null,"createdBy":"WINCHC","dateCreated":"2023-04-11","modifiedBy":"ONEDATA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Relapse","valueDescription":"Relapse","ValueMeaning":{"publicId":"5035791","version":"1","preferredName":"Relapse","longName":"5035791","preferredDefinition":"The return of signs and symptoms of cancer after a period of improvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse","conceptCode":"C0699753","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"223EE1E8-286D-61CF-E050-BB89AD436EF1","latestVersionIndicator":"Yes","beginDate":"2015-10-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F910B966-4CD8-1F7F-E053-731AD00AFFC2","beginDate":"2022-04-04","endDate":null,"createdBy":"WINCHC","dateCreated":"2023-04-11","modifiedBy":"ONEDATA","dateModified":"2023-04-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"8137610","version":"1","preferredName":"Overall Disease Response Evaluation Leukemia Type","preferredDefinition":"Including everything.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.:A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.:Something distinguishable as an identifiable class based on common qualities.","longName":"8137610v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Overall","conceptCode":"C25605","definition":"Including everything.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD766A5-2E89-5E13-E053-4EBD850AD9C1","latestVersionIndicator":"Yes","beginDate":"2022-04-04","endDate":null,"createdBy":"WINCHC","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RECISTv1.1:Response Evaluation Criteria in Solid Tumors v1.1","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F910B96D-FE8B-1F67-E053-731AD00A0E3B","latestVersionIndicator":"Yes","beginDate":"2022-04-04","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-04-11","modifiedBy":"CLOHNES","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":"4/11/23 Versioned VD to 2.0, changed max length to 100 to fit longest PV, rearranged long name in order of concepts, rearranged def to fit order of concepts. This is done as a result of cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Overall Response this reporting period?","url":null,"context":"CCTG"}],"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9115C59-95F8-3B13-E053-731AD00A97F6","latestVersionIndicator":"Yes","beginDate":"2022-04-04","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-04-11","modifiedBy":"CLOHNES","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":"4/11/23 Released CDE for CCTG cjl; 4/11/23 Versioned CDE to 2.0 due to major version of VD (due to max length and rearrangement of long name) and rearrangement of long name and addition of human readable def to CDE cjl.","unresolvedIssues":null,"deletedIndicator":"No"}}